SCHEMBL4521132

SCHEMBL4521132

Cn1c(I)nc2cc(CN3CCCC3)ccc21

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.46
PKM P14618 2/20 0.46
HDAC6 Q9UBN7 1/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
HRH3 Q9Y5N1 1/20 0.43
KDM4E B2RXH2 1/20 0.43
CHKA P35790 2/20 0.42
HTT P42858 2/20 0.42
RECQL P46063 1/20 0.42
POLB P06746 1/20 0.42
USP2 O75604 1/20 0.42
F2 P00734 1/20 0.42
MBTD1 Q05BQ5 1/20 0.41
L3MBTL3 Q96JM7 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
RAB9A P51151 2/20 0.41
NPC1 O15118 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2320716 0.74 SIGMAR1 (0.58) ALDH1A1SMN1; SMN2HRH3KDM4ECHKA
SCHEMBL20921174 0.70 KDM4E (0.50) ALDH1A1KDM4ERAB9ANPC1
SCHEMBL27423871 0.69 KDM4E (0.56) ALDH1A1SMN1; SMN2KDM4EHTTRECQL
SCHEMBL3967968 0.68 MEN1 (0.44) ALDH1A1KDM4ERAB9ANPC1
SCHEMBL31031663 0.68 MAPT (0.53) ALDH1A1SMN1; SMN2HTTUSP2RAB9A
SCHEMBL3962704 0.68 KDM4E (0.48) ALDH1A1SMN1; SMN2KDM4ERAB9ANPC1
SCHEMBL13675228 0.68 TRPC5 (0.45) ALDH1A1PKMHDAC6HRH3KDM4E
SCHEMBL21400973 0.67 HRH3 (0.53) ALDH1A1SMN1; SMN2HRH3KDM4EHTT
SCHEMBL1924005 0.67 MAP3K7 (0.52) ALDH1A1SMN1; SMN2HRH3HTTPOLB
SCHEMBL1926108 0.67 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2HRH3KDM4EHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8618132-B2 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2013-12-31 US disclosed
EP-1558578-B1 NOVEL ALKYNE COMPOUNDS HAVING AN MCH ANTAGONISTIC EFFECT AND MEDICAMENTS CONTAINING THESE COMPOUNDS BOEHRINGER INGELHEIM PHARMA (DE) 2013-03-13 EP disclosed
US-20090069282-A1 ALKYNE COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-03-12 US disclosed
US-7452911-B2 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2008-11-18 US disclosed
US-20040209865-A1 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069282-A1 ALKYNE COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS MCHR1, MCHR2, GPR119 ALDH1A1 3188/4885PKM 1901/4885HDAC6 3295/4885
US-20040209865-A1 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds MCHR1, MCHR2, NPY1R ALDH1A1 2991/4885PKM 2008/4885HDAC6 3655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.